Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 15/20 | 0.85 |
| ▸ | KCNQ2 | O43526 | 15/20 | 0.85 |
| ▸ | KCNE1 | P15382 | 11/20 | 0.85 |
| ▸ | KCNQ1 | P51787 | 11/20 | 0.85 |
| ▸ | BACE1 | P56817 | 1/20 | 0.85 |
| ▸ | RAB9A | P51151 | 1/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.73 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5214418 | 0.92 | KCNQ3 (1.00) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL5215207 | 0.90 | KCNQ3 (0.81) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL1986996 | 0.87 | KCNQ3 (0.82) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL3313800 | 0.86 | RAB9A (0.75) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL401818 | 0.86 | KCNQ3 (0.71) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL4972665 | 0.85 | KCNQ3 (0.66) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL8361559 | 0.84 | RAB9A (1.00) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL16436052 | 0.84 | KCNQ3 (0.65) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL2306301 | 0.84 | RAB9A (0.76) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL14516647 | 0.84 | RAB9A (0.72) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010143803-A2 | NEW NICOTINAMIDE DERIVATIVES WITH ANTI-ANDROGEN EFFECTS, PROCESSES OF PREPARING, AND ANTIANDROGENS COMPRISING THE SAME | INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY (KR) | 2010-12-16 | — | — | WO | claimed |
| EP-3725775-A1 | PYRIDINE- AND PYRIMIDINECARBOXAMIDES AS CXCR2 MODULATORS | Syntrix Biosystems, Inc. (US) | 2020-10-21 | — | — | EP | disclosed |
| EP-2942346-B1 | PYRIDINECARBOXAMIDES AS CXCR2 MODULATORS | SYNTRIX BIOSYSTEMS INC (US) | 2020-05-06 | — | — | EP | disclosed |
| US-RE47415-E1 | Pyrimidinecarboxamides as CXCR2 modulators | SYNTRIX BIOSYSTEMS, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-RE47267-E1 | Pyridinecarboxamides as CXCR2 modulators | SYNTRIX BIOSYSTEMS, INC. (US) | 2019-03-05 | — | — | US | disclosed |
| EP-2942346-A1 | PYRIDINE- AND PYRIMIDINECARBOXAMIDES AS CXCR2 MODULATORS | Syntrix Biosystems, Inc. (US) | 2015-11-11 | — | — | EP | disclosed |
| EP-2615092-B1 | HETEROCYCLIC AMINO BERBAMINE DERIVATIVES, PREPARATION METHOD AND USE THEREOF | HANGZHOU BENSHENG PHARMACEUTICAL CO LTD (CN) | 2015-08-26 | — | — | EP | disclosed |
| US-8987288-B2 | Heterocyclic aminoberbamine derivatives, the preparation process and use thereof | HANGZHOU BENSHENG PHARMACEUTICAL CO., LTD. (CN) | 2015-03-24 | — | — | US | disclosed |
| US-8987288-B2 | Heterocyclic aminoberbamine derivatives, the preparation process and use thereof | HANGZHOU BENSHENG PHARMACEUTICAL CO., LTD. (CN) | 2015-03-24 | — | — | US | disclosed |
| US-8981106-B2 | Pyrimidinecarboxamides as CXCR2 modulators | SYNTRIX BIOSYSTEMS, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| WO-2008073936-A1 | CARBOXAMIDE DERIVATIVES AS ION CHANNEL MODULATORS | WYETH (US) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008073936-A1 | CARBOXAMIDE DERIVATIVES AS ION CHANNEL MODULATORS | WYETH (US) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008073929-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008073934-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2008-06-19 | — | — | WO | disclosed |
| US-7151112-B1 | Pharmaceutical uses and synthesis of nicotinamides | UCB SA (GB) | 2006-12-19 | — | — | US | disclosed |
| US-7141590-B2 | Pharmaceutical uses and synthesis of nicotinanilide-N-oxides | UCB SA (GB) | 2006-11-28 | — | — | US | disclosed |
| US-20050026965-A1 | Pharmaceutical uses and synthesis of nicotinanilide-N-oxides | DARWIN DISCOVERY LIMITED (GB) | 2005-02-03 | — | — | US | disclosed |
| US-6777432-B1 | TREATING A SUBJECT HAVING AN INFLAMMATORY DISORDER ALLEVIATED BY THE INHIBITION OF GRO- ALPHA CYTOKINES | DARWIN MOLECULAR CORPORATION | 2004-08-17 | — | — | US | disclosed |
| US-20030004189-A1 | Pharmaceutical uses and synthesis of nicotinanilide-N-oxides | DARWIN DISCOVERY LTD. (GB) | 2003-01-02 | — | — | US | disclosed |
| WO-2002053544-A1 | PHARMACEUTICAL USES AND SYNTHESIS OF NICOTINANILIDE-N-OXIDES | DARWIN DISCOVERY LTD. (GB) | 2002-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004189-A1 | Pharmaceutical uses and synthesis of nicotinanilide-N-oxides | NNT, NAPRT, NNMT | KCNQ3 1517/4885KCNQ2 1152/4885KCNE1 2011/4885 |
| US-20050026965-A1 | Pharmaceutical uses and synthesis of nicotinanilide-N-oxides | NNT, NAPRT, NNMT | KCNQ3 1517/4885KCNQ2 1152/4885KCNE1 2011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.